On February 5, 2026, TrumpRx launched — a government-affiliated direct-to-patient pharmacy offering FDA-approved GLP-1 medications at prices that would have seemed impossible a year ago: Wegovy at $149–299/month versus the retail price of $1,349/month.

This is a real program. The pricing is real. But the details matter significantly.

What TrumpRx actually is

TrumpRx is a direct-to-patient pharmacy program operating under a government affordability initiative. It offers FDA-approved finished products — not compounded semaglutide, but actual brand-name Wegovy and Zepbound — at negotiated prices.

The mechanism: the administration negotiated manufacturer pricing concessions in exchange for directing patients to this channel. Novo Nordisk and Eli Lilly participate because it is better for them to sell at a discount than to watch the compounded market continue to erode their revenue.

Who qualifies

Based on current information, TrumpRx pricing is available for patients without commercial insurance coverage for these medications. Income eligibility requirements may apply. The program is limited to US residents with a valid prescription from a licensed provider.

How the prices compare

Wegovy brand-name at TrumpRx: $149–299/month (vs. retail $1,349/month) Compounded semaglutide at telehealth platforms: $99–400/month Zepbound at TrumpRx: $299–449/month (vs. retail $1,087/month)

The overlap is significant. A patient who qualifies for TrumpRx pricing and prefers brand-name FDA-approved product is paying roughly what they would pay for compounded semaglutide at a mid-tier telehealth platform.

What this means for the compounded market

It is not a coincidence that TrumpRx launched the same day Hims launched compounded semaglutide tablets, and the FDA escalated enforcement. The administration appears to be creating a government-approved low-cost alternative while simultaneously restricting the non-government alternatives.

Whether that interpretation is correct or not, the practical effect is that patients now have more legitimate pathways to affordable GLP-1 medications than they did six months ago. That is probably good for patients regardless of how the regulatory dynamics play out.